Developer docs
API playgroundTry for free, no card

Search company profiles

Lumibird Medical

Full company profile

uuid000ekdr

Namestring
Lumibird Medical
Legal namestring
LUMIBIRD MEDICAL
Company typeenum
Private
Founded yearint
1993
Descriptiontext

Lumibird Medical is the Medical division of France-headquartered, Euronext-listed Lumibird Group, established in its current form in 2020 by unifying three legacy brands — Quantel Medical (1993), Ellex (1985, Australia), and Optotek Medical (1990, Slovenia). Operating from Cournon-d'Auvergne with ISO 13485 manufacturing in Slovenia, the company designs, develops, manufactures, and sells ophthalmic medical devices across three segments: Ophthalmology (treatment lasers such as YAG/SLT and photocoagulators, diagnostic ultrasound platforms, and dry-eye diagnostic/treatment systems), Interventional Imaging (portable ultrasounds and microendoscopy), and OEM Solutions (certified laser and imaging components for other medical device manufacturers).

Its product portfolio spans premium integrated laser platforms (Tango Reflex Neo, UltraQ Reflex Neo, Vitra 2, Easyret, Integre LIO, Integre Pro), diagnostic ultrasound systems (ABSolu, Compact Touch, POCKET III, AXIalis), and the C.SUITE dry-eye ecosystem combining the AI-powered C.DIAG diagnostic platform with the C.STIM IPL treatment device. Underlying technical differentiation rests on proprietary optical and laser innovations including Reflex™ second-generation optics with True Coaxial Illumination (TCI™), SubLiminal® tissue-sparing retinal therapy, PROcap™ capsulotomy with extended posterior offset, Imprint™ heads-up display, and computer-vision diagnostic algorithms trained on over one million clinically validated ocular images.

The company monetizes primarily through direct hardware sales of capital equipment to ophthalmology practices, retina specialists, and hospitals, supplemented by after-sales service contracts and OEM supply. Go-to-market is hybrid: wholly-owned direct subsidiaries in France, Japan, Poland, Australia, the Nordics, and India (with Southeast Asia in build-out) complement a distributor network covering 110+ countries. End customers include ophthalmologists and eye-care professionals, interventional imaging specialists, OEM medical device manufacturers, and government healthcare institutions such as the Indian Ministry of Defence.

Short descriptiontext

Lumibird Medical is the Medical division of Euronext-listed Lumibird Group, developing and selling ophthalmic lasers, diagnostic ultrasound platforms, AI-powered dry-eye systems, and OEM medical imaging solutions to ophthalmologists and healthcare institutions across 110+ countries via direct subsidiaries and a global distributor network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersCournon-d'auvergne, France
HQ citystring
Cournon-d'auvergne
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic laser systems, medical ultrasound imaging, retinal photocoagulation devices, ocular diagnostic equipment, ophthalmic medical devices
Industry1 code
1Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics)
CodeHLAHAJAHPrimaryYes
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Ophthalmic Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Medical Laser Systems
TypeHardware Sales
Description

Sale of ophthalmic laser systems including retinal photocoagulators (Vitra 2, Easyret), YAG/SLT lasers (Tango Reflex Neo, UltraQ Reflex Neo), and integrated laser platforms for diagnosis and treatment of eye conditions.

lumibirdmedical.com
2Ophthalmic Ultrasound Platforms
TypeHardware Sales
Description

Sale of diagnostic ultrasound systems including A/B/S/UBM platforms (ABSolu, Compact Touch), pachymeters (POCKET III), and biometers for ophthalmic imaging and measurements.

lumibirdmedical.com
3Dry Eye Diagnostic and Treatment Solutions
TypeHardware Sales
Description

Complete C.SUITE platform including C.DIAG diagnostic platform and C.STIM IPL treatment systems for ocular surface disease management.

lumibirdmedical.com
4OEM Solutions
TypeHardware Sales
Description

Tailored, certified laser and imaging technology solutions across medical specialties, from R&D through maintenance, serving other medical device manufacturers.

lumibirdmedical.com
5After-sales Service and Maintenance
TypeProfessional Services
Description

Technical support, equipment maintenance, and after-sales service for medical devices.

lumibirdmedical.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Quantel Medical
Description

Core brand specializing in ophthalmic ultrasound platforms (A/B/S/UBM), retinal photocoagulation lasers, dry eye diagnostic and treatment solutions. Founded 1993, distributes through network in 110+ countries.

lumibirdmedical.com
+2 more records
Core offering1 text field

Lumibird Medical develops, manufactures, and sells diagnostic and therapeutic medical laser and ultrasound devices for ophthalmology, interventional imaging, and OEM applications. Operating through three complementary brands (Quantel Medical, Ellex, and Optotek Medical), the company provides solutions for cataract, glaucoma, dry eye, retinal disorders, and diabetic eye disease treatment, distributed across 110+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Reduced optical breakdown to 1.4 mJ in air (industry lowest)
+3 more records
Product overview1 text field

Lumibird Medical is the Medical division of the Lumibird Group, offering a comprehensive portfolio of diagnostic and therapeutic medical devices across three business segments: Ophthalmology, Interventional Imaging, and OEM Solutions. The product portfolio is organized under three complementary sub-brands (Quantel Medical, Ellex, and Optotek Medical) providing diagnostic ultrasound platforms (ABSolu, Compact Touch, POCKET III, AXIalis), treatment lasers (Tango Reflex Neo, UltraQ Reflex Neo, Tango Neo, Vitra 2, Easyret, Integre LIO, CAPSULO, Optimis Fusion, Solo), ocular surface diagnostic platforms (OMNICAD, C.DIAG), and dry eye treatment devices (C.STIM). Products range from premium integrated laser systems to modular platforms and handheld diagnostic devices, serving ophthalmologists worldwide through a network of distributors in over 110 countries.

Product and service2 records
1Tango Reflex Neo
CategoryTreatment Laser
Description

Premium Nd:YAG/SLT laser featuring second-generation Reflex technology with True Coaxial Illumination (TCI), PROcap capsulotomy capability, and Imprint dynamic heads-up display for anterior segment treatments. CE marked and available for sale.

2UltraQ Reflex Neo
CategoryTreatment Laser
Description

Premium Nd:YAG laser with second-generation Reflex technology featuring True Coaxial Illumination, Imprint heads-up display, and PROcap posterior capsulotomy capability with extended posterior offset up to 2mm.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1BIZ MEDIC SDN BHD
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-08
Description

Lumibird Medical announced discussions to acquire its long-term distribution partner BIZ MEDIC SDN BHD based in Kuala Lumpur, Malaysia. This move marks the future creation of Lumibird Medical Southeast Asia as a new hub for the group's growth in the region. BIZ MEDIC has been a key partner since 2004, and the acquisition will enable direct service and clinical support to surgeons and hospitals across Southeast Asia.

lumibirdmedical.com
2Centre Hospitalier National d'ophtalmologie des Quinze-Vingts
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-16
Description

Research partner in the HoloDoppler project, one of the most recognized ophthalmology centers worldwide. Collaborating on development of next-generation quantitative, non-invasive eye angiography device.

lumibirdmedical.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-16
Description

Research partner in the HoloDoppler project, working with Lumibird Medical's Quantel Medical subsidiary to develop quantitative, non-invasive retinal angiography technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-16
Description

Academic research partner in the HoloDoppler project contributing scientific expertise to the development of next-generation retinal imaging technology.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-04-24
Description

Distribution partner in China supporting Lumibird Medical's market presence. Generated €4.8M revenue in 2022, with projected 25% growth following Vitra 2 NMPA approval.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Japanese manufacturer of ophthalmic surgical and diagnostic equipment, including YAG/SLT lasers, retinal photocoagulators, and ultrasound biometry platforms. Closest Asia-Pacific peer to Lumibird Medical with directly overlapping product categories.

TypeDirect peer
Description

Specialist in retinal imaging (ultra-widefield retinal imaging devices). Competes with Lumibird Medical's retinal imaging/diagnostic platforms and is a potential HoloDoppler competitor in next-generation retinal imaging.

TypeBroad incumbent
Description

Global ophthalmic medical device and pharmaceutical leader with broad portfolio including surgical, vision care, and pharmaceutical products. Overlaps with Lumibird Medical in YAG/SLT lasers and cataract surgical workflow products but offers much wider portfolio.

TypeDirect peer
Description

Specialist in ophthalmic imaging and diagnostics including OCT, confocal laser ophthalmoscopy, and angiography. Competes with Lumibird Medical in advanced ophthalmic imaging and the HoloDoppler target category (retinal angiography).

TypeDirect peer
Description

US-based company specializing in retinal laser systems and ophthalmic surgical devices. Directly competes with Lumibird Medical's retinal photocoagulator product line (Vitra 2, Easyret, Integre Pro Scan).

TypeDirect peer
Description

Global leader in ophthalmic medical devices including surgical microscopes, lasers, and diagnostic imaging. Directly competes with Lumibird Medical in ophthalmic lasers (YAG/SLT, retinal photocoagulators) and ophthalmic diagnostic ultrasound/biometry.

TypeDirect peer
Description

US-based specialist in ophthalmic ultrasound and glaucoma diagnostics. Directly competes with Lumibird Medical's ABSolu, Compact Touch, and POCKET III ultrasound/pachymetry product lines.

TypeDirect peer
Description

Major ophthalmic device manufacturer offering optical coherence tomography, retinal imaging, and diagnostic equipment. Competes with Lumibird Medical's ultrasound and ocular surface diagnostic platforms (ABSolu, OMNICAD).

TypeBroad incumbent
Description

Acquired by Boston Scientific, medical laser specialist with ophthalmic, aesthetic, and surgical applications. Directly competes in ophthalmic lasers but operates as part of a much larger medical device conglomerate.

TypeBroad incumbent
Description

Diversified eye health company with surgical, vision care, and ophthalmic pharmaceutical segments. Competes in ophthalmic surgical devices including cataract and vitreoretinal surgery products that overlap with Lumibird Medical's cataract workflow products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries8 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lumibird Medical

Ophthalmic Medical Deviceslumibirdmedical.com

Lumibird Medical is the Medical division of Euronext-listed Lumibird Group, developing and selling ophthalmic lasers, diagnostic ultrasound platforms, AI-powered dry-eye systems, and OEM medical imaging solutions to ophthalmologists and healthcare institutions across 110+ countries via direct subsidiaries and a global distributor network.

What Lumibird Medical does

Lumibird Medical is the Medical division of France-headquartered, Euronext-listed Lumibird Group, established in its current form in 2020 by unifying three legacy brands — Quantel Medical (1993), Ellex (1985, Australia), and Optotek Medical (1990, Slovenia). Operating from Cournon-d'Auvergne with ISO 13485 manufacturing in Slovenia, the company designs, develops, manufactures, and sells ophthalmic medical devices across three segments: Ophthalmology (treatment lasers such as YAG/SLT and photocoagulators, diagnostic ultrasound platforms, and dry-eye diagnostic/treatment systems), Interventional Imaging (portable ultrasounds and microendoscopy), and OEM Solutions (certified laser and imaging components for other medical device manufacturers).

Its product portfolio spans premium integrated laser platforms (Tango Reflex Neo, UltraQ Reflex Neo, Vitra 2, Easyret, Integre LIO, Integre Pro), diagnostic ultrasound systems (ABSolu, Compact Touch, POCKET III, AXIalis), and the C.SUITE dry-eye ecosystem combining the AI-powered C.DIAG diagnostic platform with the C.STIM IPL treatment device. Underlying technical differentiation rests on proprietary optical and laser innovations including Reflex™ second-generation optics with True Coaxial Illumination (TCI™), SubLiminal® tissue-sparing retinal therapy, PROcap™ capsulotomy with extended posterior offset, Imprint™ heads-up display, and computer-vision diagnostic algorithms trained on over one million clinically validated ocular images.

The company monetizes primarily through direct hardware sales of capital equipment to ophthalmology practices, retina specialists, and hospitals, supplemented by after-sales service contracts and OEM supply. Go-to-market is hybrid: wholly-owned direct subsidiaries in France, Japan, Poland, Australia, the Nordics, and India (with Southeast Asia in build-out) complement a distributor network covering 110+ countries. End customers include ophthalmologists and eye-care professionals, interventional imaging specialists, OEM medical device manufacturers, and government healthcare institutions such as the Indian Ministry of Defence.

Lumibird Medical firmographics

Firmographics
Name
Lumibird Medical
Legal name
LUMIBIRD MEDICAL
Website
https://www.lumibirdmedical.com
Company type
Private
Founded year
1993
Operating status
Operating
Headcount range
251–500 employees
Short description
Lumibird Medical is the Medical division of Euronext-listed Lumibird Group, developing and selling ophthalmic lasers, diagnostic ultrasound platforms, AI-powered dry-eye systems, and OEM medical imaging solutions to ophthalmologists and healthcare institutions across 110+ countries via direct subsidiaries and a global distributor network.
Ownership category
akta.pro rank

Lumibird Medical industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH)

Keywords

  • Ophthalmic laser systems
  • Medical ultrasound imaging
  • Retinal photocoagulation devices
  • Ocular diagnostic equipment
  • Ophthalmic medical devices

Where Lumibird Medical is headquartered

Location

Headquarters

HQ city
Cournon-d'auvergne
HQ country
France
HQ region
Europe

Offices6 records

Markets served

Lumibird Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Medical Laser Systems: Sale of ophthalmic laser systems including retinal photocoagulators (Vitra 2, Easyret), YAG/SLT lasers (Tango Reflex Neo, UltraQ Reflex Neo), and integrated laser platforms for diagnosis and treatment of eye conditions.
  2. Ophthalmic Ultrasound Platforms: Sale of diagnostic ultrasound systems including A/B/S/UBM platforms (ABSolu, Compact Touch), pachymeters (POCKET III), and biometers for ophthalmic imaging and measurements.
  3. Dry Eye Diagnostic and Treatment Solutions: Complete C.SUITE platform including C.DIAG diagnostic platform and C.STIM IPL treatment systems for ocular surface disease management.
  4. OEM Solutions: Tailored, certified laser and imaging technology solutions across medical specialties, from R&D through maintenance, serving other medical device manufacturers.
  5. After-sales Service and Maintenance: Technical support, equipment maintenance, and after-sales service for medical devices.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

Lumibird Medical product offering

Product offering

Core offering

Lumibird Medical develops, manufactures, and sells diagnostic and therapeutic medical laser and ultrasound devices for ophthalmology, interventional imaging, and OEM applications. Operating through three complementary brands (Quantel Medical, Ellex, and Optotek Medical), the company provides solutions for cataract, glaucoma, dry eye, retinal disorders, and diabetic eye disease treatment, distributed across 110+ countries.

Product overview

Lumibird Medical is the Medical division of the Lumibird Group, offering a comprehensive portfolio of diagnostic and therapeutic medical devices across three business segments: Ophthalmology, Interventional Imaging, and OEM Solutions. The product portfolio is organized under three complementary sub-brands (Quantel Medical, Ellex, and Optotek Medical) providing diagnostic ultrasound platforms (ABSolu, Compact Touch, POCKET III, AXIalis), treatment lasers (Tango Reflex Neo, UltraQ Reflex Neo, Tango Neo, Vitra 2, Easyret, Integre LIO, CAPSULO, Optimis Fusion, Solo), ocular surface diagnostic platforms (OMNICAD, C.DIAG), and dry eye treatment devices (C.STIM). Products range from premium integrated laser systems to modular platforms and handheld diagnostic devices, serving ophthalmologists worldwide through a network of distributors in over 110 countries.

Differentiator

Problem solved

Functional benefit

Brands

  • Quantel Medical: Core brand specializing in ophthalmic ultrasound platforms (A/B/S/UBM), retinal photocoagulation lasers, dry eye diagnostic and treatment solutions. Founded 1993, distributes through network in 110+ countries.
  • Ellex
  • Optotek Medical

Products and services

  • Tango Reflex Neo Premium Nd:YAG/SLT laser featuring second-generation Reflex technology with True Coaxial Illumination (TCI), PROcap capsulotomy capability, and Imprint dynamic heads-up display for anterior segment treatments. CE marked and available for sale.
  • UltraQ Reflex Neo Premium Nd:YAG laser with second-generation Reflex technology featuring True Coaxial Illumination, Imprint heads-up display, and PROcap posterior capsulotomy capability with extended posterior offset up to 2mm.

Quantifiable outcome

  • Reduced optical breakdown to 1.4 mJ in air (industry lowest)
  • +3 more outcomes

Companies that use Lumibird Medical

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Lumibird Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability6 records

Feature6 records

Lumibird Medical partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • BIZ MEDIC SDN BHDcoreChannel Partner/ Reseller/ Distributor · 8 April 2026Lumibird Medical announced discussions to acquire its long-term distribution partner BIZ MEDIC SDN BHD based in Kuala Lumpur, Malaysia. This move marks the future creation of Lumibird Medical Southeast Asia as a new hub for the group's growth in the region. BIZ MEDIC has been a key partner since 2004, and the acquisition will enable direct service and clinical support to surgeons and hospitals across Southeast Asia.
  • Centre Hospitalier National d'ophtalmologie des Quinze-VingtscoreStrategic or Co-development Partner · 16 November 2023Research partner in the HoloDoppler project, one of the most recognized ophthalmology centers worldwide. Collaborating on development of next-generation quantitative, non-invasive eye angiography device.
  • Hôpital Fondation Adolphe de RothschildcoreStrategic or Co-development Partner · 16 November 2023Research partner in the HoloDoppler project, working with Lumibird Medical's Quantel Medical subsidiary to develop quantitative, non-invasive retinal angiography technology.
  • ESPCI PariscoreStrategic or Co-development Partner · 16 November 2023Academic research partner in the HoloDoppler project contributing scientific expertise to the development of next-generation retinal imaging technology.
  • GaushcoreChannel Partner/ Reseller/ Distributor · 24 April 2023Distribution partner in China supporting Lumibird Medical's market presence. Generated €4.8M revenue in 2022, with projected 25% growth following Vitra 2 NMPA approval.

Scale indicators7 records

Recent moves9 records

Expansion highlights7 records

Lumibird Medical competitors and assessment

Company assessment

Direct peers

  • Nidek: Japanese manufacturer of ophthalmic surgical and diagnostic equipment, including YAG/SLT lasers, retinal photocoagulators, and ultrasound biometry platforms. Closest Asia-Pacific peer to Lumibird Medical with directly overlapping product categories.
  • Optos: Specialist in retinal imaging (ultra-widefield retinal imaging devices). Competes with Lumibird Medical's retinal imaging/diagnostic platforms and is a potential HoloDoppler competitor in next-generation retinal imaging.
  • Heidelberg Engineering: Specialist in ophthalmic imaging and diagnostics including OCT, confocal laser ophthalmoscopy, and angiography. Competes with Lumibird Medical in advanced ophthalmic imaging and the HoloDoppler target category (retinal angiography).
  • Iridex: US-based company specializing in retinal laser systems and ophthalmic surgical devices. Directly competes with Lumibird Medical's retinal photocoagulator product line (Vitra 2, Easyret, Integre Pro Scan).
  • Carl Zeiss Meditec: Global leader in ophthalmic medical devices including surgical microscopes, lasers, and diagnostic imaging. Directly competes with Lumibird Medical in ophthalmic lasers (YAG/SLT, retinal photocoagulators) and ophthalmic diagnostic ultrasound/biometry.
  • Sonomed Escalon: US-based specialist in ophthalmic ultrasound and glaucoma diagnostics. Directly competes with Lumibird Medical's ABSolu, Compact Touch, and POCKET III ultrasound/pachymetry product lines.
  • Topcon Healthcare: Major ophthalmic device manufacturer offering optical coherence tomography, retinal imaging, and diagnostic equipment. Competes with Lumibird Medical's ultrasound and ocular surface diagnostic platforms (ABSolu, OMNICAD).

Broad incumbents

  • Alcon: Global ophthalmic medical device and pharmaceutical leader with broad portfolio including surgical, vision care, and pharmaceutical products. Overlaps with Lumibird Medical in YAG/SLT lasers and cataract surgical workflow products but offers much wider portfolio.
  • Lumenis (Boston Scientific): Acquired by Boston Scientific, medical laser specialist with ophthalmic, aesthetic, and surgical applications. Directly competes in ophthalmic lasers but operates as part of a much larger medical device conglomerate.
  • Bausch + Lomb: Diversified eye health company with surgical, vision care, and ophthalmic pharmaceutical segments. Competes in ophthalmic surgical devices including cataract and vitreoretinal surgery products that overlap with Lumibird Medical's cataract workflow products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Lumibird Medical compliance and trust

Trust signal

Compliance5 records

Lumibird Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lumibird Medical leadership team

Management profile

Number of profiles

Profiles5 records

Lumibird Medical subsidiaries and ownership

Company hierarchy

Subsidiaries8 records

Lumibird Medical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lumibird Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lumibird Medical

What does Lumibird Medical do?

Lumibird Medical develops, manufactures, and sells diagnostic and therapeutic medical laser and ultrasound devices for ophthalmology, interventional imaging, and OEM applications. Operating through three complementary brands (Quantel Medical, Ellex, and Optotek Medical), the company provides solutions for cataract, glaucoma, dry eye, retinal disorders, and diabetic eye disease treatment, distributed across 110+ countries.

Is Lumibird Medical a public or private company?

Lumibird Medical is a private company. It is classified as corporate owned and is currently operating.

When was Lumibird Medical founded?

Lumibird Medical was founded in 1993. It employs 251 to 500 people.

Where is Lumibird Medical based?

Lumibird Medical is headquartered in Cournon-d'auvergne, France, in the Europe region.

How does Lumibird Medical make money?

Five revenue lines are on record. Medical Laser Systems are the primary driver. The others are ophthalmic Ultrasound Platforms, dry Eye Diagnostic and Treatment Solutions, OEM Solutions and after-sales Service and Maintenance.

Who are Lumibird Medical's main competitors?

Direct peers on record are Nidek, Optos, Heidelberg Engineering, Iridex, Carl Zeiss Meditec, Sonomed Escalon and Topcon Healthcare. Broad incumbents are Alcon, Lumenis (Boston Scientific) and Bausch + Lomb.

Does Lumibird Medical have an API?

No public API is recorded for Lumibird Medical.

What industry is Lumibird Medical in?

Lumibird Medical's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAH, Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaIPG Photonics Can Fix The Revenue Hole — The Margin Math Is Harder (NASDAQ:IPGP)IPG Photonics faces a 22% revenue decline from 2023 to 2025, driven by weakness in materials-processing and high-power CW lasers. The company is monitoring recovery via industrial subsystems and a potential Lumibird Medical acquisition, but restoring gross profit requires margins back to 40%-42%. The stock is rated Hold with best-case upside of about 22%.FinancialContent Business PageLumibird signe un contrat de cession d'actions pour la vente de Lumibird Medical à IPG Photonics CorporationLumibird signed a share sale contract on September 8, 2026, for IPG Photonics' acquisition of Lumibird Medical. The deal is valued at €300 million, with a potential earn-out up to €50 million based on 2026-2027 performance. The transaction could close in Q4 2026, subject to AMF conditions and a shareholder vote on October 20.YahooIPG Photonics Q2 Earnings Call HighlightsIPG Photonics reported second-quarter revenue of $279 million, up 11% year-over-year and marking the third consecutive quarter of double-digit growth, with industrial solutions led by battery-welding applications driving performance. The company also agreed to acquire Lumibird Medical, which it expects to expand its medical addressable market by approximately $1 billion. For the third quarter, IPG forecast revenue of $265 million to $295 million while flagging an estimated 150-basis-point tariff impact on gross margin.Quiver QuantitativeIPG Photonics Reports Second-Quarter 2026 Results, Raises Gross Margin on 11% Revenue Growth and Updates Q3 Outlook | IPGP Stock NewsIPG Photonics reported second-quarter 2026 revenue of $278.6 million, an 11% year-over-year increase driven by 16% growth in its Industrial Solutions segment, which accounts for 85% of total revenue. The company's adjusted gross margin improved to 40.7% and adjusted EBITDA rose 54% to $48.5 million, though GAAP net income fell 21% to $5.2 million due to $17.6 million in impairment charges. IPG also announced Q3 2026 revenue guidance of $265 million to $295 million and highlighted its recently announced acquisition of Lumibird Medical to expand into medical markets.BioSpaceIPG Photonics Announces Second Quarter 2026 Financial ResultsIPG Photonics reported Q2 2026 revenue of $278.6 million, up 11% year-over-year, with adjusted gross margin of 40.7% and adjusted EPS of $0.58. Industrial Solutions sales grew 16%, while Advanced Solutions fell 9%. The company guided Q3 revenue to $265–295 million and adjusted EPS to $0.30–0.60.The Motley FoolWhy IPG Photonics Rallied TodayIPG Photonics shares rose 7.9% after Q2 earnings showed a revenue miss but an adjusted EPS beat. Management guided Q3 revenue to $280 million, above analyst expectations, citing strength in battery and semiconductor lasers. The company remains in recovery mode with a 31.4% year-to-date gain.GlobeNewswireIPG Photonics Announces Second Quarter 2026 Financial ResultsIPG Photonics reported Q2 2026 revenue of $278.6 million, up 11% year-over-year, with adjusted gross margin of 40.7% and adjusted EPS of $0.58. Industrial Solutions sales grew 16%, while Advanced Solutions fell 9%. The company guided Q3 revenue to $265–295 million and adjusted EPS to $0.30–0.60.Investing.comIPG Photonics earnings up next: Can margins sustain recovery? By Investing.comIPG Photonics Corporation is scheduled to report second-quarter earnings on Tuesday, with analysts forecasting EPS of $0.35 on revenue of $280 million, representing sequential improvement from Q1 results and an 11.7% year-over-year revenue increase with earnings more than doubling. The company is pursuing a margin recovery strategy targeting 40-45% gross margins, up from 37.6% recently, alongside an acquisition of Lumibird Medical for up to €350 million announced in mid-July that would roughly triple its medical business. Wall Street maintains a buy rating with a mean price target of $131.93 implying 55% upside, as investors assess whether the company's pivot toward higher-margin applications can sustain its profitability recovery.Photonics SpectraIPG Negotiating Purchase of Lumibird’s Medical DivisionIPG Photonics has entered into a binding offer to acquire Lumibird Medical for an enterprise value of €300 million ($343M), with a potential earn-out of up to €50 million based on future performance in 2026 and 2027. The acquisition would combine IPG's capabilities with Lumibird Medical's established leadership in ophthalmology and urology, creating a scaled medical laser platform with more than 450 employees and three global facilities. The transaction is expected to close in Q4 2026, subject to customary closing conditions and completion of the French works council consultation process.Simply Wall StIPG Photonics (IPGP) Targets Lumibird Medical, Is The Stock Still Undervalued?IPG Photonics has signed a binding offer to acquire Lumibird Medical, a move designed to expand its medical laser business and reshape its Advanced Solutions revenue mix. The stock is currently trading at $104.33, representing a 20.1% discount to an analyst fair value estimate of $130.50, with new growth initiatives in medical lasers, semiconductors, and micromachining being cited as potential catalysts. The company faces ongoing pressure from tariff and geopolitical risks alongside softer materials processing demand that could challenge the growth assumptions underlying the valuation premium.